123 related articles for article (PubMed ID: 38673919)
21. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
[TBL] [Abstract][Full Text] [Related]
22. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study.
Hoke M; Dieckmann K; Koppensteiner R; Schillinger M; Marosi C; Mlekusch W
Wien Klin Wochenschr; 2011 Apr; 123(7-8):199-203. PubMed ID: 21442202
[TBL] [Abstract][Full Text] [Related]
24. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples.
Kirches E; Krause G; Warich-Kirches M; Weis S; Schneider T; Meyer-Puttlitz B; Mawrin C; Dietzmann K
Int J Cancer; 2001 Aug; 93(4):534-8. PubMed ID: 11477557
[TBL] [Abstract][Full Text] [Related]
25. A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools.
Thuy MN; Kam JK; Lee GC; Tao PL; Ling DQ; Cheng M; Goh SK; Papachristos AJ; Shukla L; Wall KL; Smoll NR; Jones JJ; Gikenye N; Soh B; Moffat B; Johnson N; Drummond KJ
J Clin Neurosci; 2015 May; 22(5):785-99. PubMed ID: 25698544
[TBL] [Abstract][Full Text] [Related]
26. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
27. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C; Wang Q; Yan X; Wang J
Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
[TBL] [Abstract][Full Text] [Related]
28. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
29. Probabilistic radiographic atlas of glioblastoma phenotypes.
Ellingson BM; Lai A; Harris RJ; Selfridge JM; Yong WH; Das K; Pope WB; Nghiemphu PL; Vinters HV; Liau LM; Mischel PS; Cloughesy TF
AJNR Am J Neuroradiol; 2013 Mar; 34(3):533-40. PubMed ID: 22997168
[TBL] [Abstract][Full Text] [Related]
30. The identification of mitochondrial DNA variants in glioblastoma multiforme.
Yeung KY; Dickinson A; Donoghue JF; Polekhina G; White SJ; Grammatopoulos DK; McKenzie M; Johns TG; St John JC
Acta Neuropathol Commun; 2014 Jan; 2():1. PubMed ID: 24383468
[TBL] [Abstract][Full Text] [Related]
31. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
[TBL] [Abstract][Full Text] [Related]
32. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
34. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
[TBL] [Abstract][Full Text] [Related]
35. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
36. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
[TBL] [Abstract][Full Text] [Related]
37. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
[TBL] [Abstract][Full Text] [Related]
38.
Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
[No Abstract] [Full Text] [Related]
39. EGFLAM correlates with cell proliferation, migration, invasion and poor prognosis in glioblastoma.
Chen J; Zhang J; Hong L; Zhou Y
Cancer Biomark; 2019; 24(3):343-350. PubMed ID: 30829611
[TBL] [Abstract][Full Text] [Related]
40. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients.
Leiss L; Mega A; Olsson Bontell T; Nistér M; Smits A; Corvigno S; Rahman MA; Enger PØ; Miletic H; Östman A
Glia; 2020 May; 68(5):979-988. PubMed ID: 31769546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
